Baker Bros. Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Baker Bros. Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.12B	Hold	2,141,701	–	–	6.44%	4
2025 Q4	$1.25B	Hold	2,141,701	–	–	7.3%	3
2025 Q3	$982M	Buy	2,141,701 +165,683	+8%	+$61.8M	7.1%	3
2025 Q2	$598M	Buy	1,976,018 +1,428	+0.1%	+$425K	5.8%	6
2025 Q1	$654M	Hold	1,974,590	–	–	7.24%	4
2024 Q4	$609M	Hold	1,974,590	–	–	6.51%	4
2024 Q3	$419M	Hold	1,974,590	–	–	4.34%	5
2024 Q2	$553M	Buy	1,974,590 +4,792	+0.2%	+$1.14M	7.07%	4
2024 Q1	$526M	Hold	1,969,798	–	–	6.6%	4
2023 Q4	$456M	Buy	1,969,798 +424,685	+27%	+$74.3M	5.19%	4
2023 Q3	$226M	Hold	1,545,113	–	–	1.3%	6
2023 Q2	$357M	Hold	1,545,113	–	–	2.07%	5
2023 Q1	$374M	Hold	1,545,113	–	–	2.04%	5
2022 Q4	$448M	Buy	1,545,113 +45,900	+3%	+$4.49M	2.69%	7
2022 Q3	$97.4M	Hold	1,499,213	–	–	0.64%	15
2022 Q2	$107M	Hold	1,499,213	–	–	0.61%	12
2022 Q1	$147M	Hold	1,499,213	–	–	0.85%	9
2021 Q4	$127M	Hold	1,499,213	–	–	0.62%	14
2021 Q3	$120M	Hold	1,499,213	–	–	0.53%	17
2021 Q2	$146M	Hold	1,499,213	–	–	0.64%	15
2021 Q1	$175M	Hold	1,499,213	–	–	0.76%	15
2020 Q4	$167M	Hold	1,499,213	–	–	0.63%	15
2020 Q3	$178M	Buy	1,499,213 +1	+0%	+$109	0.71%	16
2020 Q2	$170M	Hold	1,499,212	–	–	0.75%	14
2020 Q1	$100M	Buy	1,499,212 +329,934	+28%	+$27.5M	0.62%	18
2019 Q4	$107M	Hold	1,169,278	–	–	0.57%	19
2019 Q3	$101M	Hold	1,169,278	–	–	0.69%	16
2019 Q2	$123M	Hold	1,169,278	–	–	0.83%	13
2019 Q1	$146M	Hold	1,169,278	–	–	0.94%	11
2018 Q4	$132M	Hold	1,169,278	–	–	1.08%	10
2018 Q3	$250M	Hold	1,169,278	–	–	1.65%	9
2018 Q2	$327M	Buy	1,169,278 +553,594	+90%	+$97.2M	2.46%	8
2018 Q1	$71.9M	Hold	615,684	–	–	0.61%	20
2017 Q4	$56.5M	Buy	615,684 +557,922	+966%	+$31.9M	0.49%	23
2017 Q3	$2.6M	Hold	57,762	–	–	0.02%	90
2017 Q2	$939K	Hold	57,762	–	–	0.01%	100
2017 Q1	$890K	Hold	57,762	–	–	0.01%	103
2016 Q4	$861K	Hold	57,762	–	–	0.01%	110
2016 Q3	$732K	Sell	57,762 -2	-0%	-$19	0.01%	119
2016 Q2	$526K	Buy	+57,764	New	+$693K	0.01%	125
2015 Q2	–	Sell	-13,973	Closed	-$949K	–	128
2015 Q1	$949K	Sell	13,973 -313	-2%	-$26.8K	0.01%	121
2014 Q4	$1.32M	Hold	14,286	–	–	0.01%	106
2014 Q3	$1.5M	Hold	14,286	–	–	0.02%	90
2014 Q2	$2.04M	Hold	14,286	–	–	0.03%	88
2014 Q1	$2.15M	Hold	14,286	–	–	0.03%	86
2013 Q4	$2.62M	Hold	14,286	–	–	0.04%	76
2013 Q3	$3.15M	Sell	14,286 -25,687	-64%	-$5.46M	0.04%	65
2013 Q2	$6.98M	Buy	+39,973	New	+$10.4M	0.14%	41

Other funds holding MDGL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baker Bros. Advisors's MDGL Position: Q1 2026 in Review

Baker Bros. Advisors held its Madrigal Pharmaceuticals (MDGL) position steady in Q1 2026 at 2,141,701 shares worth $1.12B. The position accounts for 6.44% of the portfolio, ranked #4.

Baker Bros. Advisors first reported a position in MDGL in Q2 2013 and has held it in 48 quarters since. The position peaked at $1.25B in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

Baker Bros. Advisors held 2,141,701 shares of Madrigal Pharmaceuticals worth $1.12B as of Q1 2026.
Baker Bros. Advisors left its Madrigal Pharmaceuticals share count unchanged in Q1 2026.
Madrigal Pharmaceuticals made up 6.44% of Baker Bros. Advisors's portfolio in Q1 2026, its #4 holding.
Baker Bros. Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
Baker Bros. Advisors's Madrigal Pharmaceuticals position peaked at $1.25B in Q4 2025.
378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.